171 related articles for article (PubMed ID: 36351720)
21. Nonsurgical salvage options for locally recurrent prostate cancer after primary definitive radiotherapy: a systematic review and meta-analysis.
Yang J; Xiong X; Liao X; Zheng W; Xu H; Wei Q; Yang L
Int J Surg; 2024 May; 110(5):3008-3020. PubMed ID: 38348896
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of salvage high dose-rate brachytherapy with or without pelvic external beam radiotherapy in patients with palpable local recurrence of prostate cancer after radical prostatectomy.
Ni L; Chen K; Phuong C; Sabbagh AR; Wong AC; Mohamad O; Hsu IC
Brachytherapy; 2023; 22(3):304-309. PubMed ID: 36623988
[TBL] [Abstract][Full Text] [Related]
23. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
[TBL] [Abstract][Full Text] [Related]
24. Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.
Fuller D; Wurzer J; Shirazi R; Bridge S; Law J; Crabtree T; Mardirossian G
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):291-299. PubMed ID: 31629838
[TBL] [Abstract][Full Text] [Related]
25. A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy.
Hegde JV; Collins SP; Fuller DB; King CR; Demanes DJ; Wang PC; Kupelian PA; Steinberg ML; Kamrava M
Am J Clin Oncol; 2018 May; 41(5):502-507. PubMed ID: 27322703
[TBL] [Abstract][Full Text] [Related]
26. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R; Gides D; Horriot R
Int J Med Sci; 2008 Jun; 5(3):113-20. PubMed ID: 18566673
[TBL] [Abstract][Full Text] [Related]
27. Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma?
Klein J; Ghasem A; Huntley S; Donaldson N; Keisch M; Conway S
Clin Orthop Relat Res; 2018 Mar; 476(3):634-644. PubMed ID: 29443850
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse.
Kinj R; Doyen J; Hannoun-Lévi JM; Naghavi AO; Chand ME; Baudin G; Ferrero JM; François E; Evesque L; Borchiellini D; Benezery K; Bondiau PY
Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e15-e21. PubMed ID: 32641243
[TBL] [Abstract][Full Text] [Related]
29. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
30. Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer.
Chatzikonstantinou G; Keller C; Scherf C; Bathen B; Köhn J; Tselis N
Brachytherapy; 2021; 20(1):44-49. PubMed ID: 32826171
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study.
Alayed Y; Loblaw A; Chu W; Al-Hanaqta M; Chiang A; Jain S; Chung H; Vesprini D; Morton G; Ravi A; Davidson M; Deabreu A; Mamedov A; Zhang L; Erler D; Cheung P
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1066-1073. PubMed ID: 31002941
[TBL] [Abstract][Full Text] [Related]
32. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
[TBL] [Abstract][Full Text] [Related]
33. GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol.
Pasquier D; Le Deley MC; Tresch E; Cormier L; Duterque M; Nenan S; Lartigau E
BMJ Open; 2019 Aug; 9(8):e026666. PubMed ID: 31377694
[TBL] [Abstract][Full Text] [Related]
34. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.
Shaverdian N; Verruttipong D; Wang PC; Kishan AU; Demanes DJ; McCloskey S; Kupelian P; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):516-525. PubMed ID: 28126301
[TBL] [Abstract][Full Text] [Related]
35. Timing of High-Dose Rate Brachytherapy With External Beam Radiotherapy in Intermediate and High-Risk Localized Prostate CAncer (THEPCA) Patients and Its Effects on Toxicity and Quality of Life: Protocol of a Randomized Feasibility Trial.
Palvai S; Harrison M; Shibu Thomas S; Hayden K; Green J; Anderson O; Romero L; Lodge R; Burns P; Ahmed I
JMIR Res Protoc; 2015 Apr; 4(2):e49. PubMed ID: 25926023
[TBL] [Abstract][Full Text] [Related]
36. Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma.
Walter F; Nierer L; Rottler M; Duque AS; Weingandt H; Well J; Shpani R; Landry G; Seidensticker M; Streitparth F; Ricke J; Belka C; Corradini S
Radiat Oncol; 2021 May; 16(1):86. PubMed ID: 33957941
[TBL] [Abstract][Full Text] [Related]
37. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
[TBL] [Abstract][Full Text] [Related]
38. Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes.
Lewin R; Amit U; Laufer M; Berger R; Dotan Z; Domachevsky L; Davidson T; Portnoy O; Tsvang L; Ben-Ayun M; Weiss I; Symon Z
Radiat Oncol; 2021 Jun; 16(1):114. PubMed ID: 34162398
[TBL] [Abstract][Full Text] [Related]
39. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy - preliminary results.
Jo Y; Fujii T; Hara R; Yokoyama T; Miyaji Y; Yoden E; Hiratsuka J; Nagai A
BJU Int; 2012 Mar; 109(6):835-9. PubMed ID: 21933327
[TBL] [Abstract][Full Text] [Related]
40. Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer.
Dincer N; Ugurluer G; Mustafayev TZ; Serkizyan A; Aydin G; Güngör G; Yapici B; Atalar B; Özyar E
Brachytherapy; 2024; 23(1):18-24. PubMed ID: 38000958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]